Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +2.50p +0.79% 320.00p 315.00p 325.00p 320.00p 317.50p 317.50p 29,519 16:25:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 20.3 4.0 8.1 39.7 137.64

Tristel Share Discussion Threads

Showing 3076 to 3099 of 3100 messages
Chat Pages: 124  123  122  121  120  119  118  117  116  115  114  113  Older
DateSubjectAuthorDiscuss
10/5/2018
09:08
Amati AIM VCT significantly upped their position.
glaws2
08/5/2018
23:15
- member since 08 May 2018 - same on various sites > > > filtered
piedro
08/5/2018
22:16
Automatically earn 10$ in your account when you register a free account in this investment platform, i have tried it and earn the 10$ give away bonus it true, you check it out and earn yours now https://jmktradings.com
frankpondish
08/5/2018
11:41
FWIW, TSTL Level II chart, - showing the bid and the offer spread
piedro
26/4/2018
09:02
I think we are about to move out of our trading range to new highs. Lots of good US to come and all completed by year end and first revenues from there in this FY. I expect 350p in short order.
mach100
23/4/2018
09:16
Good jump today and looks like it wasn;t priced in as we head to record highs. This was 314p mid in August and we could surpass that unless Profit takers move in on the rise. The fact that the revenue will come in the current financial year helps as well as completion by year end. A significant risk has been removed and with some good news flow of states' approval tis could help teh share price to 400p.
mach100
23/4/2018
07:40
I think we followers are already loaded up as the only possible surprise would be to not get approval. It is, however, a game changer for the press adding more certainty of US income initially followed by everyone else. Not only is the US the largest healthcare market, but also the most litigious. I can't imagine any facility wanting to risk litigation over hospital-acquired infection because they were not using the best cleaning agent available (as confirmed by many independent tests).
melton john
23/4/2018
07:19
Approval received! Still a long road ahead before we see revenues from US sales but good news nevertheless. Be interesting to see if this announcement has any effect 9n the share price...
zimbtrader
23/4/2018
07:18
EPA approval received Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the United States Environmental Protection Agency ("EPA") has registered its foam-based chlorine dioxide product, Duo. This registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces. The federal registration will be followed by state-by-state approvals which the Company expects to complete by the end of 2018. The Company anticipates first revenues from the United States during its 2018-19 financial year. Paul Swinney, CEO of Tristel plc, comments: "We have achieved our first United States regulatory approval, and we will continue to pursue further registrations with the EPA and the Food and Drug Administration ("FDA") to build a broadly-based business in the USA. "We recently announced that we have appointed Parker Laboratories Inc to manufacture Duo in its FDA approved facility in New Jersey, and to sell Duo into the ultrasound marketplace in which they have national sales coverage. We will sell our products through different channels into other clinical areas in the USA hospital market. "This first United States approval is a very significant step for our Company as it enables us to access the largest healthcare market in the world. It has been our long-held ambition to be recognised as a global brand in the infection prevention industry. An active presence in the United States is necessary to achieve this ambition, and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal." hTtp://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/TSTL/13613667.html
metis20
23/4/2018
07:17
RNS issued this morning confirming that EPA approval has been secured.
james188
20/4/2018
16:24
My thoughts exactly,Glaws.I was really surprised when they announced the target date at the interims presentations back in February and added that they had no reason to expect that date to move backwards. You have to admire the transparency, but it did slightly up the ante. Hopefully the approval will follow shortly. I also wonder who is going to be the Duo distributor for non-ultrasound uses. The RNS las month announcing the collaboration with Parker said that Parker would manufacture Duo for the Americas and market it "in the ultrasound market place".
james188
20/4/2018
15:57
No news yet of the EPA approval. Due date was 16th April - although as it's government......
glaws2
20/4/2018
15:18
FWIW, New Tristel Science Paper: #Chlorinedioxide #high-level #disinfectant #wipes: a published data review https://tinyurl.com/ycy9q5vf
piedro
21/3/2018
16:24
Highlighted by Tristel Global and Ecomed SA/NV Using Chemical Microbicides to Interrupt the Environmental Spread of Pathogens By Andrew Duong Edited by: Michael Diamond April 18, 2017 hxxps://infectioncontrol.tips/2017/04/18/using-chemical-microbicides/
piedro
14/3/2018
03:09
FWIW, FDA Warns Duodenoscope Manufacturers About Failure to Comply With Postmarket Surveillance Studies to Assess Contamination Mar 12, 2018 https://tinyurl.com/y8e78jcj
piedro
05/3/2018
12:30
NEW? The Clean Academy The Clean Academy provides objectively-researched and evidence-based articles regarding trending topics in the healthcare industry, ranging from organisms and infections of concern to best practice in infection prevention and control. http://www.tristel.com/resources/the-clean-academy
piedro
27/2/2018
16:40
CVSG - as it's buying up many vet practices they are purchasing in bulk and forcing prices down.
glaws2
27/2/2018
13:17
They are going to keep both Anistel & Crystel going - they are trying to move both to CL02 chemistry but admit it is a slow process. Meanwhile they are both profitable and generate cash. They are getting margin pressure on Anistel from the buying power of CVSG
glaws2
27/2/2018
13:08
Thank you Glaws2 for observations Good to see you got some feedback on product development One question I forgot to ask was about their plans for Anistel and Crystel On page 4 of the presentation they are clearly of the "other products" class and possibly only exist to give economy to those of Tristel.
piedro
27/2/2018
10:23
Some brief notes from last week's presentation - read in conjunction with Maynard Paton's report (above)which makes most of the key points. Good to see real growth returning to overseas sales. Hong Kong – signalled at the 2017 Final results presentation that they were looking to run this directly (cf Australia). Did £222k in H1 – a drop of nearly 40% compared to last year’s comparative period. Historically used to do £0.6 - 0.7m pa. Goood potential for rapid growth here – as seen in Australia. Stated that there were not looking at any other acquisitions at present. During the period, started 55 new regulatory dossiers and 82 were submitted to authorities. Received 15 approvals. Initial exploratory work commenced on India and Japan. Keen to stress that never had a rejection. This regulatory activity will provide the future growth and additional products are coming on stream in existing and new markets. Mobile ODT – no revenue as yet as most of these are sold in the US. Developed App (uses voice recognition so can be operated hands free) for use with ODT which gives instructions on when to disinfect. No sales until EPS approval. Significant US revenue still a few years away. New product – Shot – hoping that this will invigorate UK sales- launching in May. It will be a hard sell as although have now got price compatibility it is more fiddly than pre-impregnated wipes (but is a higher level disinfectant). Historically £0.2 – 0.3m pa spent on new product development (£0.2m in H1). Almost all reach the market. The majority at least recoup their development costs. Products also morph over time and can lead to further products – eg Shot coming out of Puffin. Some still being worked on – eg the baby products – see this as a big market if they can develop an effective way to use on incubators.
glaws2
23/2/2018
18:57
Phil Oakley of Sharescope/Sharepad includes an appraisal of TSTL amongst others in this week’s roundup. It’s behind a paywall but I can say that his analyses are always balanced and worth reading, and favorable in this case, rather more so than Maynard Paton. I hold btw for the long term for further growth and IHT relief - very long term I hope :-)
dozey3
23/2/2018
14:37
Maynard Paton ... Tristel: H1 Results Boast 24% Profit Jump Before North American Costs As EPA Decision Now Set For 16 April 23 February 2018 By Maynard Paton https://tinyurl.com/yapklawy
piedro
23/2/2018
14:21
Cambridge news ... Tristel's overseas success drives growth Numbers look good for contamination control firm By Matt Gooding 23 FEB 2018 https://tinyurl.com/y92xxu2c
piedro
20/2/2018
15:26
Whilst awaiting presentation feedback ... - and perhaps a comment Tristel sometimes publishes events on twitter, sometimes their website, facebook or linkedin ... Tristel Global We are exhibiting at the 33rd Asia-Pacific Academy of Ophthalmology (APAO) Congress from the 8th to the 11th of February. Visit Stand 3K-14 to find out what Tristel Duo can achieve in 30 seconds. - kind of confused / confusing / confusion !!
piedro
Chat Pages: 124  123  122  121  120  119  118  117  116  115  114  113  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180523 03:39:51